Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Weight loss was still increasing at Week 36, implying Kailera and Hengrui Pharma can go past 22.8%. The data suggest HRS9531 has similar efficacy to Eli Lilly’s Zepbound. Patients taking the ...

Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable prescription medication ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks ...

This change could expand access to Zepbound, which is not yet widely covered by Medicare or other insurance plans for weight loss. In December, the FDA approved Zepbound as the first and only ...

For Zepbound’s 10mg weekly dose, the average weight loss was 22.2 kg (48.9 lb), and for Zepbound’s 15mg weekly dose average weight loss was 23.6 kg (52.0 lb) over 72 weeks. Patients who used a ...

Doctors warn about their physical side effects, but they can also have unexpected effects on intimacy. Jeanne and Javier, who have been married for 15 years.Credit...Katherine Wolkoff for The New ...